Drugs / HCP1803-4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07660796 | Jul 2026 → Oct 2027 expected | essential hypertension | Hanmi Pharmaceutical Company Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1803-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660796 ↗ |
| Route | Oral | “take HCP1803-4 once daily for 8 weeks orally” NCT07660796 ↗ |